One compound, the dual ALK/MET tyrosine kinase inhibitor (TKI), was the first-in-class ALK TKI used in clinics for ALK+ ALCL [6] and has been shown to be effective in refractory/relapsed cases [7]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.